-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inflammatory protein expression in endothelial cells and preliminary data showcasing the potential anti-inflammatory mechanism of icosapent ethyl (IPE) via modulation of nod-like recepto ...

Core Viewpoint - The article identifies Pfizer, Summit Therapeutics, and Vertex Pharmaceuticals as strong investment opportunities in the pharmaceutical sector, highlighting their growth potential and current market conditions. Group 1: Pfizer - Pfizer is considered a top stock in healthcare due to its low valuation, high yield, and growth prospects, appealing to both dividend and growth investors [3][7] - Despite facing challenges this year related to tariffs and healthcare reform, Pfizer's underlying financials remain solid, with an adjusted EPS guidance increase to between $2.90 and $3.10 from a previous forecast of $2.80 to $3.00 [4] - The company has seen strong growth across major segments, including primary care (12%), specialty care (7%), and oncology (11%), and currently offers a dividend yield of around 6.7% [5] Group 2: Summit Therapeutics - Summit Therapeutics has experienced a significant stock increase of nearly 2,000% over three years, now holding a market cap of $18 billion [8] - The leading candidate, ivonescimab, has shown promising results in clinical trials for non-small cell lung cancer, potentially challenging the market leader, Keytruda [9][10] - Analysts project ivonescimab could generate approximately $4.4 billion in sales by 2030, indicating substantial future growth potential [11] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals' stock has declined over 20% due to recent pipeline setbacks, but it is viewed as a buying opportunity [13] - The company has three new products expected to drive significant sales growth, including Alyftrek for cystic fibrosis and Casgevy for rare blood disorders [14] - Vertex's new pain medication, Journavx, is gaining traction, and the company is investing in its sales and marketing efforts [15] - Vertex's PEG ratio is notably low at 0.58, suggesting it is undervalued relative to its growth prospects [17]

Core Viewpoint - The article emphasizes the importance of holding high-yield dividend stocks for the long term, highlighting five specific companies that demonstrate sustainability in their dividends and growth potential. Group 1: AbbVie - AbbVie has successfully navigated the patent cliff of its leading drug Humira, which previously accounted for over 60% of its sales, and continues to grow despite declining sales from this drug [3][4] - The company has invested in research and development and made strategic acquisitions, positioning itself for long-term success [4] - AbbVie is recognized as a Dividend King, having increased its dividend for 53 consecutive years, with a payout increase of 310% since its spin-off from Abbott Labs in 2013, currently yielding 3.16% [5] Group 2: Enbridge - Enbridge operates with a low-risk, utility-like business model, transporting 30% of North America's crude oil and 20% of the U.S. natural gas, making it a stable investment [7][8] - The company is the largest natural gas utility in North America and is investing in renewable energy, projecting $50 billion in growth opportunities through the end of the decade [8] - Enbridge has a forward dividend yield of 5.71% and has increased its dividend for 30 consecutive years [9] Group 3: Enterprise Products Partners - Enterprise Products Partners is a midstream energy leader with over 50,000 miles of pipeline, transporting various energy products [10] - Unlike Enbridge, it does not operate a natural gas utility and is structured as a limited partnership, which may involve tax complexities [11] - The company offers a high distribution yield of 6.82% and has increased its distribution for 27 consecutive years [11] Group 4: Realty Income - Realty Income has provided positive operational returns every year since its NYSE listing in 1994, supported by a diversified property portfolio with 1,630 clients across 91 industries [12][13] - The company employs a triple-net-lease business model, transferring most costs to tenants, and has significant growth opportunities in Europe [13] - Realty Income currently yields 5.55% and has increased its payout for 30 consecutive years [14] Group 5: Verizon Communications - Verizon is one of the largest wireless providers globally, benefiting from high entry barriers in the wireless network market [15] - Despite past performance challenges, the company is currently generating industry-leading wireless service revenue and has potential growth with the rollout of 6G networks by the end of the decade [16] - Verizon's dividend yield is 6.17%, and it has increased its dividend for 18 consecutive years, with expectations for continued growth [17]

Group 1 - The core point of the article is that China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration [1]

Core Insights - Novo Nordisk presented data from the STEER real-world study at the ESC Congress 2025, highlighting the cardiovascular benefits of Wegovy (semaglutide 2.4 mg) compared to tirzepatide in patients with obesity and established cardiovascular disease (CVD) without diabetes [1][4]. Group 1: Study Findings - Wegovy demonstrated a significant 57% greater risk reduction for major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular-related death compared to tirzepatide in patients without treatment gaps exceeding 30 days [2][8]. - In all treated individuals, Wegovy showed a 29% risk reduction for heart attack, stroke, and death from any cause compared to tirzepatide over an average follow-up of 8.3 months for Wegovy and 8.6 months for tirzepatide [3][8]. - The STEER study adds to the evidence that the heart-protective benefits of Wegovy are specific to the semaglutide molecule and not applicable to other GLP-1 or GIP/GLP-1-based treatments [8]. Group 2: Study Design and Population - The STEER study was a retrospective, observational study evaluating the efficacy of Wegovy versus tirzepatide for preventing MACE in US adults aged 45 and older with overweight or obesity and established CVD without prior diabetes [6][7]. - The study included 10,625 individuals in each treatment group, with researchers using propensity score matching to ensure comparability between Wegovy and tirzepatide users [7]. Group 3: Context of Cardiovascular Disease and Obesity - Cardiovascular disease (CVD) is the leading cause of disability and death globally, with nearly 21 million deaths annually. Obesity significantly contributes to cardiovascular morbidity and mortality [5]. - Despite a decrease in overall cardiovascular mortality over the past two decades, obesity-related cardiovascular deaths have risen, with two-thirds of such deaths linked to CVD [5].

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1This study adds to gro ...

Alnylam Pharmaceuticals (ALNY) Update / Briefing August 30, 2025 01:00 PM ET Company ParticipantsPushkal Garg - Executive VP, Chief Research & Development OfficerBryan Williams - Chair - Medicine & ProfessorNeha Pagidipati - Associate Professor of MedicineSimon Fox - VP - Zilebesiran Program LeadManu Chakravarthy - Senior VP, Global Head - Cardiovascular, Renal & Metabolism Product DevelopmentEllie Merle - Executive Director - Biotech Equity ResearchPushkal GargHello, everybody, and thank you for joining us ...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company’s progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year. The study is investigating a novel, non-invasive treatment option. Bokhari confirmed that Medicus Pharma has requested a Type C meeting with the US Food and Drug Administ ...

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo plus LLT1 Basel, August 30, 2025 – ...

Core Viewpoint - Dividend-paying stocks can provide regular income and potential stock price appreciation, often overlooked by investors focused on high-growth stocks [1] Dividend Performance Summary - Dividend growers and initiators have an average annual total return of 10.24% from 1973 to 2024, while dividend payers yield 9.20%, and non-payers yield only 4.31% [3] Company Summaries Realty Income - Realty Income (O) has a dividend yield of 5.5% and is a REIT that pays dividends monthly, having paid dividends for over 660 months [4][5] - The company owns 15,600 leased properties across 91 industries, with major clients including 7-Eleven and Home Depot [6] - Realty Income's forward P/E ratio is 37, below its five-year average of 42, indicating attractive valuation [6] Pfizer - Pfizer (PFE) offers a dividend yield of 6.8%, with recent stock price declines attributed to reduced demand for Covid-19 products and patent expirations [7] - The company has a strong drug pipeline, with over 50 programs and a focus on oncology, and reported a 10% year-over-year revenue increase [7] - Pfizer's forward P/E ratio is 8.2, significantly below its five-year average of 10.1, suggesting appealing valuation [7] Verizon Communications - Verizon (VZ) has a dividend yield of 6.1% and extensive infrastructure, including over a million miles of fiber and 146.1 million wireless retail connections [8][9] - The company faces challenges with subscriber growth but generates substantial free cash flow of approximately $20 billion over the last year [9] - Verizon's forward P/E ratio is 9.3, close to its five-year average of 9.0, indicating reasonable valuation [10] United Parcel Service - United Parcel Service (UPS) has a dividend yield of 7.5%, with recent share price declines due to various operational challenges [11][12] - The company is addressing issues such as reduced online shopping demand and higher employee costs, with a focus on strategic initiatives for long-term growth [12][13] - UPS's commitment to improving financial performance suggests potential for recovery and growth [13]